China shares snap rally as experimental vaccines stoke safety concerns


BEIJING/SHANGHAI: China stocks snapped a three-session rally to close lower on Wednesday, with consumer and healthcare shares leading losses, as experts were concerned over the safety of drugs used in experimental coronavirus vaccines in the country.

At the close, the Shanghai Composite index was down 0.36% at 3,283.92.

The blue-chip CSI300 index was down 0.66%, with its financial sector sub-index slipping 0.23%, while the real estate index closed 1% firmer.

Healthcare and consumer shares fell, with the consumer staples sector losing 1.81% and the healthcare sub-index down 1.83%.

Shanghai Fosun Pharmaceutical Group Co dropped 5% to the lowest in nearly two months, while index heavyweight Kweichow Moutai shed 1.9%.

The smaller Shenzhen index ended down 0.91% and the start-up board ChiNext Composite index was weaker by 1.555%.

China is inoculating tens of thousands of its citizens with experimental vaccines. Aiming to reduce the likelihood of a resurgence, the vaccines are also grabbing attention in the global scramble by governments to secure supplies, potentially helping reframe China's perceived role in the pandemic.

Subscribe now and receive FREE sooka plan for 1 month.
T&C applies.

Monthly Plan

RM13.90/month

Annual Plan

RM12.33/month

Billed as RM148.00/year

1 month

Free Trial

For new subscribers only


Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!

Shanghai Composite index , CSI300

   

Next In Business News

Ringgit strengthens against greenback ahead of OPR decision
Trading ideas: IOI, Gagasan Nadi, Xin Hwa, T7, TCS, Aneka, HE, Ann Joo, Aimflex, F&N
Toyota likely to post first profit drop in two years
Strong financial grasp critical for investors
Licence freeze to have impact on Xin Hwa
Gagasan Nadi in RM185mil acquisition
Proton October sales climb 13.6% to 12,799 units
Aneka Jaringan wins RM39mil job
TCS bags RM86mil contract
The Philippines to be cautious in policy easing cycle

Others Also Read